Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;61(2):618-25.
doi: 10.1007/s10620-015-3982-4. Epub 2015 Dec 10.

Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation

Lindsay A Uribe  1 , Nghia Nguyen  2 , Lily Kim  3 , Huy N Trinh  4 , Christopher Wong  5 , Clifford Wong  5 , Long H Nguyen  6 , Mindie H Nguyen  7
Affiliations

Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation

Lindsay A Uribe et al. Dig Dis Sci. 2016 Feb.

Abstract

Background and aims: Chronic hepatitis B (CHB) is a major cause of cirrhosis and end-stage liver disease. Not all patients with CHB require antiviral treatment but long-term monitoring is critical to identify patients who would benefit from antiviral therapy. CHB patients followed in various clinical settings may differ in disease characteristics and rates of treatment eligibility in long-term follow-up.

Methods: We conducted a retrospective cohort study of 359 consecutive treatment-naive, treatment-ineligible CHB patients (228 from community GI clinics; 73 from university hepatology clinic; 58 from primary care clinic). Primary end points were the proportion of patients meeting eligibility criteria in follow-up, and the eligibility comparison among patients in various clinical settings. Univariate and multivariate Cox's proportional hazard models were used to calculate hazard ratios to identify predictors of treatment eligibility in follow-up.

Results: While the majority of patients remained treatment ineligible by guideline recommendations, a sizeable proportion (23 %, 95 % CI 18-27 %) of patients subsequently met treatment eligibility in study follow-up. Reasons for meeting US Panel treatment eligibility on multivariate analysis included baseline ALT ≥ ULN (HR 1.91, p = 0.03) and baseline HBV DNA ≥ 2000 IU/mL (HR 2.6, p = 0.001). Practice setting was not a predictor.

Conclusions: A significant number of patients with CHB (23 %) who were not initially treatment eligible later met treatment criteria in longer-term follow-up. Significant independent predictors of treatment eligibility included a baseline ALT ≥ ULN and elevated HBV DNA (≥2000 IU/mL for US Panel eligibility and ≥20,000 IU/mL for AASLD eligibility). This study underscores the importance of long-term follow-up for patients with CHB.

Keywords: Chronic hepatitis B; Long-term follow-up; Treatment eligibility.

PubMed Disclaimer

References

    1. Dig Dis Sci. 2013 Dec;58(12):3626-33 - PubMed
    1. Dig Dis Sci. 2012 May;57(5):1373-83 - PubMed
    1. Clin Gastroenterol Hepatol. 2008 Dec;6(12 ):1315-41; quiz 1286 - PubMed
    1. J Viral Hepat. 2011 Jul;18(7):449-57 - PubMed
    1. N Engl J Med. 2002 May 30;346(22):1682-3 - PubMed

LinkOut - more resources